{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-352126","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-08-14T20:00:21+00:00","discovered_at":"2026-08-14T20:03:10.227799+00:00","generated_at":"2026-08-14T20:03:19.840095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cue Biopharma Q2 net loss $153M, revenue $7.9M, $50M PIPE","bullets":["Q2 revenue $7.9M vs $3.0M YoY; net loss $153.1M vs $8.5M, driven by one-time charges.","R&D expenses $49.0M incl. $20M cash to Ascendant and $20M warrant fair value; G&A $46.6M incl. $23M integration and $19.7M stock comp.","Cash $17.4M at June 30; completed $50M private placement after quarter-end.","Submitted IND to FDA for CUE-221 in food allergy; Phase 2 data in chronic spontaneous urticaria expected by end of Q3 2026.","Appointed Dr. Dominic Borie as CMO/Head of R&D and James M. Ahlers as CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-352126","json":"https://secwatch.observer/filing/0001193125-26-352126.json","markdown":"https://secwatch.observer/filing/0001193125-26-352126.md","text":"https://secwatch.observer/filing/0001193125-26-352126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/0001193125-26-352126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:03:19.840095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}